Kristian Reich, MD, PhD, discussed a therapeutic breakthrough with bimekizumab, a novel biologic in development that inhibits IL-17F in addition to IL-17A.
Kristian Reich, MD, PhD, discussed a therapeutic breakthrough with bimekizumab, a novel biologic in development that inhibits IL-17F in addition to IL-17A.
Kristian Reich, MD, PhD,...